He is a physician-researcher with extensive experience in Mexico, currently serving as Director of Research and Development at Laboratorios Silanes. Under his leadership, the company has promoted the development of multiple innovative drugs—in areas such as type 2 diabetes, dyslipidemia, chronic pain, and metabolic diseases, as well as biotechnological treatments. Among his contributions, the development of the molecule “metformin glycinate” and the exploration of its repositioning for the treatment of COVID-19 stand out. In addition, he is the author of dozens of scientific articles on metabolism, chronic diseases, pharmacology, and infectious diseases.
Dr. González Canudas advocates that research should be geared toward responding to “real health needs”—prioritizing prevalent diseases in Mexico such as diabetes, obesity, hypertension, and cardiovascular diseases—with the aim of transforming the national pharmaceutical industry into a driver of innovation and social welfare.